The KRT19 Knockout A2780 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal cell population for studying KRT19 loss in ovarian cancer. Generated from A2780 cells, this model pools cells with targeted disruptions in the KRT19 gene, encoding cytokeratin 19. The polyclonal format avoids clonal selection bias and provides a robust loss-of-function tool for cytoskeletal and signaling research.
A2780 is an epithelial ovarian carcinoma cell line established from an untreated patient, widely used for metastasis and drug resistance studies. These cells maintain epithelial characteristics and responsiveness to chemotherapeutics, making them a relevant host for investigating cytoskeletal gene function in a cancer context.
KRT19, a type I intermediate filament protein, heterodimerizes with KRT8 to form keratin networks essential for epithelial architecture. KRT19 interacts with beta-catenin, 14-3-3 proteins, PKC, and AKT, and its expression is regulated by transcription factors GATA3, FOXA1, SOX9, p63 and signals like EGF and TGF-beta. Downstream, KRT19 modulates E-cadherin, vimentin, and MMP expression, influencing beta-catenin/TCF/LEF activity. Its loss may disrupt RhoA-ROCK-LIMK-cofilin and PI3K/AKT/mTOR pathways, promoting cytoskeletal reorganization and EMT.
In A2780 cells, KRT19 knockout likely impairs keratin filament integrity, altering cell adhesion and morphology. This mimics EMT, marked by reduced E-cadherin and increased vimentin, potentially enhancing migration and invasion. The model enables dissection of how cytoskeletal disruption impacts ovarian cancer progression, circulating tumor cell biology, and apoptosis resistance, particularly through cross-talk with Wnt and PI3K/AKT signaling.
Applications include western blotting, RT-qPCR, immunofluorescence, wound healing, and Transwell invasion assays to study migration and invasion. Flow cytometry, caspase activity assays, and MTT assays facilitate apoptosis and drug resistance studies. Co-immunoprecipitation and RNA-seq can probe protein interactions and transcriptomic changes. This product supports EMT research, biomarker validation, and mechanistic cancer studies. For further information, contact Ascent Research.
